Biltmore Family Office LLC Boosts Holdings in Johnson & Johnson $JNJ

Biltmore Family Office LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 16.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 20,132 shares of the company’s stock after purchasing an additional 2,785 shares during the period. Biltmore Family Office LLC’s holdings in Johnson & Johnson were worth $3,733,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $28,000. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Semmax Financial Advisors Inc. grew its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter valued at about $35,000. Finally, Signature Resources Capital Management LLC increased its holdings in Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. Raymond James Financial boosted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Guggenheim increased their price target on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a report on Wednesday, December 17th. Finally, Wolfe Research lifted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $226.18.

Johnson & Johnson Stock Up 0.6%

JNJ opened at $221.54 on Tuesday. The stock has a market capitalization of $533.76 billion, a P/E ratio of 20.05, a price-to-earnings-growth ratio of 2.14 and a beta of 0.34. Johnson & Johnson has a one year low of $141.50 and a one year high of $222.17. The business’s 50-day simple moving average is $208.79 and its 200-day simple moving average is $189.84. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. During the same quarter in the previous year, the firm posted $2.04 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.